Incidence of bone metastases in patients with solid tumors: analysis of oncology electronic medical records in the United States

被引:262
作者
Hernandez, Rohini K. [1 ]
Wade, Sally W. [2 ]
Reich, Adam [3 ]
Pirolli, Melissa [3 ]
Liede, Alexander [5 ]
Lyman, Gary H. [4 ]
机构
[1] Amgen Inc, One Amgen Ctr Dr, Thousand Oaks, CA 91320 USA
[2] Wade Outcomes Res & Consulting, 358 South 700 East,Suite B432, Salt Lake City, UT 84102 USA
[3] IMS Hlth, 1 IMS Dr, Plymouth Meeting, PA 19462 USA
[4] Univ Washington, Sch Med, Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N, Seattle, WA 98109 USA
[5] Amgen Inc, 1120 Vet Blvd, San Francisco, CA 94114 USA
关键词
Solid tumor; Bone metastasis; Incidence; Epidemiology; SKELETAL-RELATED EVENTS; POPULATION-BASED ANALYSIS; PROSTATE-CANCER; BREAST-CANCER; HEALTH; MORTALITY; SURVIVAL; BENEFICIARIES; PREVENTION; PATTERNS;
D O I
10.1186/s12885-017-3922-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Bone metastases commonly occur in conjunction with solid tumors, and are associated with serious bone complications. Population-based estimates of bone metastasis incidence are limited, often based on autopsy data, and may not reflect current treatment patterns. Methods: Electronic medical records (OSCER, Oncology Services Comprehensive Electronic Records, 569,000 patients, 52 US cancer centers) were used to identify patients >= 18 years with a solid tumor diagnosis recorded between 1/1/2004 and 12/31/2013, excluding patients with hematologic tumors or multiple primaries. Each patient's index date was set to the date of his or her first solid tumor diagnosis in the selection period. Kaplan-Meier analyses were used to quantify the cumulative incidence of bone metastasis with follow-up for each patient from the index date to the earliest of the following events: last clinic visit in the OSCER database, occurrence of a new primary tumor or bone metastasis, end of study (12/31/2014). Incidence estimates and associated 95% confidence intervals (CI) are provided for up to 10 years of follow-up for all tumor types combined and stratified by tumor type and stage at diagnosis. Results: Among 382,733 study patients (mean age 64 years; mean follow-up 940 days), breast (36%), lung (16), and colorectal (12%) tumors were most common. Mean time to bone metastasis was 400 days (1.1 years). Cumulative incidence of bone metastasis was 2.9% (2.9-3.0) at 30 days, 4.8% (4.7-4.8) at one year, 5.6% (5.5-5.6) at two years, 6.9% (6.8-7.0) at five years, and 8.4% (8.3-8.5) at ten years. Incidence varied substantially by tumor type with prostate cancer patients at highest risk (18% - 29%) followed by lung, renal or breast cancer. Cumulative incidence of bone metastasis increased by stage at diagnosis, with markedly higher incidence among patients diagnosed at Stage IV of whom 11% had bone metastases diagnosed within 30 days. Conclusions: These estimates of bone metastasis incidence represent the experience of a population with longer follow-up than previously published, and represent experience in the recent treatment landscape. Underestimation is possible given reliance on coded diagnoses but the clinical detail available in electronic medical records contributes to the accuracy of these estimates.
引用
收藏
页数:11
相关论文
共 29 条
[1]   Payer Costs for Inpatient Treatment of Pathologic Fracture, Surgery to Bone, and Spinal Cord Compression Among Patients with Multiple Myeloma or Bone Metastasis Secondary to Prostate or Breast Cancer [J].
Barlev, Arie ;
Song, Xue ;
Ivanov, Boris ;
Setty, Vidya ;
Chung, Karen .
JOURNAL OF MANAGED CARE PHARMACY, 2010, 16 (09) :693-702
[2]   Survival in patients with breast cancer with bone metastasis: a Danish population-based cohort study on the prognostic impact of initial stage of disease at breast cancer diagnosis and length of the bone metastasis-free interval [J].
Cetin, Karynsa ;
Christiansen, Christian Fynbo ;
Svaerke, Claus ;
Jacobsen, Jacob Bonde ;
Sorensen, Henrik Toft .
BMJ OPEN, 2015, 5 (04)
[3]   Bone metastasis, skeletal-related events, and mortality in lung cancer patients: A Danish population-based cohort study [J].
Cetin, Karynsa ;
Christiansen, Christian Fynbo ;
Jacobsen, Jacob Bonde ;
Norgaard, Mette ;
Sorensen, Henrik Toft .
LUNG CANCER, 2014, 86 (02) :247-254
[4]   Bone health in cancer patients: ESMO Clinical Practice Guidelines [J].
Coleman, R. ;
Body, J. J. ;
Aapro, M. ;
Hadji, P. ;
Herrstedt, J. .
ANNALS OF ONCOLOGY, 2014, 25 :124-137
[5]   Metastatic bone disease and the role of biochemical markers of bone metabolism in benign and malignant diseases [J].
Coleman, RE .
CANCER TREATMENT REVIEWS, 2001, 27 (03) :133-135
[6]   Metastasis and bone loss: Advancing treatment and prevention [J].
Coleman, Robert E. ;
Lipton, Allan ;
Roodman, G. David ;
Guise, Theresa A. ;
Boyce, Brendon F. ;
Brufsky, Adam M. ;
Clezardin, Philippe ;
Croucher, Peter I. ;
Gralow, Julie R. ;
Hadji, Peyman ;
Holen, Ingunn ;
Mundy, Gregory R. ;
Smith, Matthew R. ;
Suva, Larry J. .
CANCER TREATMENT REVIEWS, 2010, 36 (08) :615-620
[7]   Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer [J].
DePuy, Venita ;
Anstrom, Kevin J. ;
Castel, Liana D. ;
Schulman, Kevin A. ;
Weinfurt, Kevin P. ;
Saad, Fred .
SUPPORTIVE CARE IN CANCER, 2007, 15 (07) :869-876
[8]   NCCN Task Force Report: Bone Health in Cancer Care [J].
Gralow, Julie R. ;
Biermann, J. Sybil ;
Farooki, Azeez ;
Fornier, Monica N. ;
Gagel, Robert F. ;
Kumar, Rashmi N. ;
Shapiro, Charles L. ;
Shields, Andrew ;
Smith, Matthew R. ;
Srinivas, Sandy ;
Van Poznak, Catherine H. .
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2009, 7 :S1-S32
[9]   Incidence of bone metastases in breast cancer patients in the United Kingdom: Results of a multi-database linkage study using the general practice research database [J].
Hagberg, Katrina Wilcox ;
Taylor, Aliki ;
Hernandez, Rohini Khorana ;
Jick, Susan .
CANCER EPIDEMIOLOGY, 2013, 37 (03) :240-246
[10]  
Hernandez RK, 2014, AM COLL EP ANN M